All In MedTech

Device Trial Radar · NCT04303897

Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma

A Real-World Evidence Study to Evaluate the Safety and Effectiveness of XEN Glaucoma Treatment System (XEN) in Chinese Patients With Refractory Glaucoma

Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Dec 19, 2019

Primary completion

Mar 3, 2022

Study completion Mar 3, 2022

Sponsor

Lead sponsor
AllerganNot on our public-company list
Sponsor type
Industry
First posted
Mar 11, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma. Participants will be (prospective) or have already been (retrospective) implanted with XEN via specific urgent medical need.

Conditions

  • Refractory Glaucoma

Interventions

  • XEN Glaucoma StentDevice

    Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients achieving at least a 20% reduction from intraocular pressure (IOP) while on the same number or fewer number of IOP lowering medications than at baselineTime frame: Baseline to Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boao Super Hospital /ID# 233669

    Qionghai, Hainan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.